Victoria Tovar
Overview
Explore the profile of Victoria Tovar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, et al.
Gastroenterology
. 2019 Jul;
157(5):1383-1397.e11.
PMID: 31344396
Background & Aims: Cirrhosis and chronic inflammation precede development of hepatocellular carcinoma (HCC) in approximately 80% of cases. We investigated immune-related gene expression patterns in liver tissues surrounding early-stage HCCs...
2.
Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian C, Roberto M, et al.
Gut
. 2016 Nov;
66(7):1286-1296.
PMID: 27849562
Objective: Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive...
3.
Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, et al.
Gastroenterology
. 2016 Sep;
151(6):1192-1205.
PMID: 27614046
Background & Aims: Effective treatments are urgently needed for hepatocellular carcinoma (HCC), which is usually diagnosed at advanced stages. Signaling via the insulin-like growth factor (IGF) pathway is aberrantly activated...
4.
Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, et al.
Gut
. 2015 Dec;
66(3):530-540.
PMID: 26658144
Objective: Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. Molecular mechanisms underlying acquired resistance are still unknown. Herein, we characterise the role of tumour-initiating cells...
5.
Pinyol R, Tovar V, Llovet J
J Hepatol
. 2014 May;
61(3):685-7.
PMID: 24859456
No abstract available.
6.
Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al.
Gastroenterology
. 2013 Jan;
144(4):829-40.
PMID: 23295441
Background & Aims: Cholangiocarcinoma, the second most common liver cancer, can be classified as intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma. We performed an integrative genomic analysis of ICC samples from...
7.
Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, et al.
Gastroenterology
. 2011 Feb;
140(5):1618-28.e16.
PMID: 21324318
Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous tumor that develops via activation of multiple pathways and molecular alterations. It has been a challenge to identify molecular classes of...
8.
Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al.
Gastroenterology
. 2011 Feb;
140(5):1501-12.e2.
PMID: 21320499
Background & Aims: In approximately 70% of patients with hepatocellular carcinoma (HCC) treated by resection or ablation, disease recurs within 5 years. Although gene expression signatures have been associated with...
9.
Zender L, Villanueva A, Tovar V, Sia D, Chiang D, Llovet J
J Hepatol
. 2010 Apr;
52(6):921-9.
PMID: 20385424
Hepatocellular carcinoma (HCC) is a deadly cancer, whose incidence is increasing worldwide. Albeit the main risk factors for HCC development have been clearly identified, such as hepatitis B and C...
10.
Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang D, Sole M, et al.
J Hepatol
. 2010 Mar;
52(4):550-9.
PMID: 20206398
Background & Aims: IGF signaling has a relevant role in a variety of human malignancies. We analyzed the underlying molecular mechanisms of IGF signaling activation in early hepatocellular carcinoma (HCC;...